M&R Capital Management Inc. Sells 219 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

M&R Capital Management Inc. lessened its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 1.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,151 shares of the financial services provider’s stock after selling 219 shares during the period. M&R Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $2,252,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Accurate Wealth Management LLC bought a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $31,000. MADDEN SECURITIES Corp bought a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $69,000. Phocas Financial Corp. bought a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $56,000. McGuire Investment Group LLC increased its holdings in iShares Biotechnology ETF by 9.6% during the 4th quarter. McGuire Investment Group LLC now owns 66,815 shares of the financial services provider’s stock worth $8,772,000 after acquiring an additional 5,836 shares during the period. Finally, Coldstream Capital Management Inc. bought a new stake in iShares Biotechnology ETF during the 4th quarter worth approximately $798,000. Institutional investors own 58.02% of the company’s stock.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock traded down $2.24 during midday trading on Friday, reaching $124.50. 2,630,843 shares of the stock were exchanged, compared to its average volume of 1,594,135. The company’s fifty day moving average is $131.94 and its 200-day moving average is $128.93. iShares Biotechnology ETF has a 52 week low of $104.29 and a 52 week high of $138.74.

About iShares Biotechnology ETF

(Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.